News

MorphoSys gets milestone from Novartis; acquires new technology

21-10-2014

German company MorphoSys says it has received a milestone payment from Novartis in connection with the…

BiotechnologyLanthio PharmalanthipeptideMergers & AcquisitionsMorphoSysNovartisOphthalmicsResearch

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Proteon Thera gets new funding of $15 million, ahead of Novartis acquisition option

15-08-2011

US privately-held biopharmaceutical firm Proteon Therapeutics, the subject of a takeover option by Swiss…

BiotechnologyFinancialMergers & AcquisitionsNovartisPharmaceuticalProteon TherapeuticsResearch

Silence Thera receives takeover approach from unnamed drug firm

07-09-2010

UK-based drug developer Silence Therapeutics (AIM: SLN) saw its share price skyrocket 76% to 12.75 pence…

AstraZenecaBiotechnologyDainippon Sumitomo PharmaMergers & AcquisitionsNovartisPharmaceuticalSilence Therapeutics

A New lease of life for Big Pharma, by David Stevenson, writing for MoneyWeek

23-12-2009

Few people – or businesses – were buoyed up by last week’s UK Pre-Budget Report (PBR).…

Abbott LaboratoriesBiotechnologyFinancialGeneralGenericsGlaxoSmithKlineGSKLicensingMarkets & MarketingMerck KGaAMergers & AcquisitionsNovartisparoxetinePatentsPaxilPfizerPharmaceuticalPneumococcal 7-valent ConjugatePoliticsPrevnarPricingRegulationRofecoxibSolvayVioxxWyeth

Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid

22-12-2009

US stem-cell specialist Athersys’ shares rocketed almost 200% to $2.96 after it revealed yesterday…

AnidulafunginAntibiotics and Infectious diseasesBiotechnologyEraxisGastro-intestinalsGlaxoSmithKlineGSKHumulin 70-30Humulin NHumulin RInsulinLicensingMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalRoche

Back to top